Streetbeat News

Earnings

CYH

MEIP

SCYX

VYGR

XCUR

Benzinga Insights has identified several healthcare sector value stocks based on low P/E ratios. These include Exicure (XCUR), Voyager Therapeutics (VYGR), MEI Pharma (MEIP), SCYNEXIS (SCYX), and Community Health Systems (CYH). The article provides recent earnings per share (EPS) data for these companies, noting changes from previous quarters. While value stocks offer potential for growth, there is a risk they may not rebound.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:44 pm

DADA

Dada Nexus Limited has announced preliminary estimates indicating that approximately RMB 500 million in revenues from online advertising and marketing services, as well as RMB 500 million in operations and support costs, may have been overstated.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:41 pm

DADA

Dada Nexus Limited reported that during an internal audit, suspicious practices were identified that could affect the legitimacy of some of its 2023 revenues from online advertising and marketing services.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:40 pm

GCO

Genesco Inc. reported disappointing comparable sales and has reduced its fiscal year 2024 outlook, leading to a decline in its stock price.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:40 pm

AIRC

FPH

RMR

SEVN

The article provides an overview of notable value stocks in the real estate sector, focusing on their price-to-earnings (P/E) ratios and recent financial performance. Ready Capital, Seven Hills Realty Trust, Five Point Holdings, RMR Group, and Apartment Income REIT are highlighted for their low P/E ratios, suggesting they may be undervalued. The article includes details on earnings per share (EPS) and dividend yields, noting changes from previous quarters.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:39 pm

SMMT

Summit Therapeutics Inc. (NASDAQ:SMMT) presented updated Phase II data for ivonescimab at the 42nd Annual J.P. Morgan Healthcare Conference. The data showed promising results in patients with non-small cell lung cancer (NSCLC), including a 24-month overall survival rate of 64.8% in first-line squamous NSCLC patients and a median overall survival of 22.5 months in second or third line EGFRm NSCLC patients. Summit is advancing ivonescimab into two global Phase III clinical trials and expects catalyst events in Q2 2024 for two randomized Phase III trials conducted by Akeso in China. Summit reported a preliminary unaudited balance of cash and investments of no less than $186 million as of December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:36 pm

DTC

Solo Brands has revised its full-year 2023 revenue guidance downward, which is now below market estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:35 pm

BAC

BLK

JPM

SPY

WFC

Equity markets are facing pressure as investors await Q4 earnings season for guidance on the potential continuation of the late 2023 rally. The S&P 500 and SPDR S&P 500 ETF (SPY) experienced their first loss after nine weeks of gains. Factors contributing to market uncertainty include high stock valuations, over-optimistic Federal Reserve rate cut expectations, geopolitical tensions, and economic slowdown concerns. Earnings from major financial firms like Bank of America (BAC), BlackRock (BLK), CitiGroup (C), JPMorgan Chase (JPM), and Wells Fargo (WFC) this week are highly anticipated as they may set the tone for the overall earnings season and 2024 outlooks. Zacks estimates a marginal Q4 earnings growth for S&P 500 companies, and consumer sentiment appears to be improving with expectations of easing inflation and potential Fed rate cuts.

Portfolio Pulse from Neil Dennis

January 08, 2024 | 2:34 pm

NVAX

Novavax is initiating a new cost reduction program aimed at further reducing R&D and SG&A expenses. The goal is to drive total expenses below $750 million for the year 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:33 pm

PTCT

PTC Therapeutics projects its FY24 revenue to be between $600M and $850M, which spans below and above the current estimate of $652.89M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:31 pm